Skip to main content
SpringerLink
Log in

Bevacizumab + INF-α-2a: safer and therefore less costly in mRCC

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Silva CI, Monteiro I, Schwander B.Cost Analysis of Managing Adverse Events in the Treatment of Metastatic Renal Cell Carcinoma in Portugal: a Comparison of Bevacizumab in Combination with Interferon Alfa-2A and Sunitinib. 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: abstr. PCN40, 6 Nov 2010. Available from: URL: http://www.ispor.org

  2. Carlos F, Ramirez J, Aguirre A.Costs of Managing Adverse Events of First-Line Therapy for Metastatic Renal Cell Carcinoma in Mexico: Bevacizumab in Combination with Interferon-Alpha-2A Compared with Sunitinib. 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: abstr. PCN42, 6 Nov 2010. Available from: URL: http://www.ispor.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bevacizumab + INF-α-2a: safer and therefore less costly in mRCC. React. Wkly. 1329, 1 (2010). https://doi.org/10.2165/00128415-201013290-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201013290-00001

Keywords

Search

Navigation